Таратухин Е. О. Артериальная гипертензия и ишемическая болезнь сердца: место антагонистов рецепторов ангиотензина II. Кардиоваскулярная терапия и профилактика. 2012;11(6):78-80.
1. Zhao H, Li M, Wang L, et al. Angiotensin II induces TSLP via an AT1 receptor, promoting Th17 differentiation. Cell Physiol Biochem 2012; 30(6): 1383-97.
2. Fang J, Ma L, Zhang S, et al. Association of myeloperoxidase gene variation with carotid atherosclerosis in patients with arterial hypertension. Mol Med Report 2012; Oct,23: 267.
3. Kishi T, Hirooka Y, Konno S, et al. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 2012; 30(8): 1646-55.
4. Miyata M, Ikeda Y, Nakamura S, et al. Effects of valsartan on fibrinolysis in hypertensive patients with metabolic syndrome. Circ J 2012; 76(4): 843-51.
5. Putnam K, Shoemaker R, Yiannikouris F, et al. The renin-angiotensin system: a target and contributor to dyslipidemias, altered glucose homeostasis and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol 2012; 302(6): 1219-30.
6. Baehr IN, Tretter P, Krueger J, et al. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-gamma in patients with the metabolic syndrome. Hypertension 2011; 58: 725-32.
7. Simonenko VB, Medvedev IN, Tolmachev VV. Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan. Klin Med 2011; 89: 35-8.
8. Fogari R, Zoppi A, Mugellini A, et al. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertens Res 2011; 34: 1321-6.
9. Murad JP, Espinosa EV, Ting HJ, et al. Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan. J Cardiovasc Pharmacol Ther 2012; 17(3): 308-14.
10. Rossi GP. Losartan metbolite EXP3179. Hypertension 2009; 54: 710-2.
11. Ono K, Ueda H, Yoshizawa Y, Akazawa D, et al. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan via glycoprotein VI. J Med Chem 2010; 53(5): 2087-93.
12. Lee B-S, Choi JY, Kim JY, et al. Simvastatin and losartan differentially and synergistically inhibit atherosclerosis in apolipoprotein E-- mice. Korean Circ J 2012; 42(8): 543-50.
13. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-92.
14. Mourad AA, Heeba GH, Taye A, et al. Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. Fundam Clin Pharmacol 2012; May,21.
15. Akhavan MM, Karimi M, Ghodrati M, et al. AT1 receptors activation enhances the expression of MMP-2, MMP-13 and VEGF but not MMP-9 in B16F10 melanoma cells. Pak J Biol Sci 2011; 14(17): 821-30.
16. Choi CH, Park YA, Choi JJ, et al. Angiotensin II type 1 receptor and miR-155 endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cnacer cells. Gynecol Oncol 2012; 126(1): 124-31.
17. Li M, Liu J, Han C, et al. Angiotensin II induces the expression of c-reactive protein via MAPK-dependent signal pathway in U937 macrophages. Cell Physiol Biochem 2011; 27(1): 63-70.
18. Thatcher SE, Zhang X, Howatt DA, et al. Angiotensin-converting enzyme 2 deficiency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor -/- mice. Arterioscler Thromb Vasc Biol 2011; 31(4): 758-65.
19. Sardo MA, Mandraffino G, Riggio S, et al. Effects of the angiotensin II receptort blocker losartan on the monocyte expression of biglycan in hypertensive patients. Clin Exp Pharmacol Physiol 2010; 37(9): 933-8.
